Evoke Pharma Stock Performance
| EVOK Stock | USD 30.80 1.10 3.70% |
Evoke Pharma holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.66, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evoke Pharma will likely underperform. Use Evoke Pharma semi variance, and the relationship between the treynor ratio and daily balance of power , to analyze future returns on Evoke Pharma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evoke Pharma are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Evoke Pharma disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Last Split Factor 1:12 | Last Split Date 2024-08-01 |
1 | Insider Trading | 12/01/2025 |
2 | Disposition of 15509 shares by Donofrio Matthew J of Evoke Pharma at 11.0 subject to Rule 16b-3 | 12/16/2025 |
3 | Acquisition by Garner Cam L of 17750 shares of Evoke Pharma at 2.12 subject to Rule 16b-3 | 02/02/2026 |
Evoke Pharma Relative Risk vs. Return Landscape
If you would invest 1,069 in Evoke Pharma on November 20, 2025 and sell it today you would earn a total of 1,901 from holding Evoke Pharma or generate 177.83% return on investment over 90 days. Evoke Pharma is currently generating 2.4621% in daily expected returns and assumes 16.0076% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Evoke, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evoke Pharma Target Price Odds to finish over Current Price
The tendency of Evoke Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 30.80 | 90 days | 30.80 | about 5.82 |
Based on a normal probability distribution, the odds of Evoke Pharma to move above the current price in 90 days from now is about 5.82 (This Evoke Pharma probability density function shows the probability of Evoke Stock to fall within a particular range of prices over 90 days) .
Evoke Pharma Price Density |
| Price |
Predictive Modules for Evoke Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evoke Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evoke Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evoke Pharma is not an exception. The market had few large corrections towards the Evoke Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evoke Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evoke Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.12 | |
β | Beta against Dow Jones | 2.66 | |
σ | Overall volatility | 6.68 | |
Ir | Information ratio | 0.14 |
Evoke Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evoke Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evoke Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evoke Pharma is way too risky over 90 days horizon | |
| Evoke Pharma appears to be risky and price may revert if volatility continues | |
| Evoke Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10.25 M. Net Loss for the year was (5.35 M) with profit before overhead, payroll, taxes, and interest of 13.99 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02. | |
| Evoke Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Insider Trading |
Evoke Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evoke Stock often depends not only on the future outlook of the current and potential Evoke Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evoke Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.9 M | |
| Cash And Short Term Investments | 13.6 M |
Evoke Pharma Fundamentals Growth
Evoke Stock prices reflect investors' perceptions of the future prospects and financial health of Evoke Pharma, and Evoke Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evoke Stock performance.
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 12.48 M | ||||
| Shares Outstanding | 1.72 M | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 5.64 X | ||||
| Price To Sales | 1.31 X | ||||
| Revenue | 10.25 M | ||||
| Gross Profit | 13.99 M | ||||
| EBITDA | 353.31 K | ||||
| Net Income | (5.35 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 5.16 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | 1.56 X | ||||
| Cash Flow From Operations | (5.46 M) | ||||
| Earnings Per Share | (1.38) X | ||||
| Market Capitalization | 18.95 M | ||||
| Total Asset | 17.52 M | ||||
| Retained Earnings | (128.79 M) | ||||
| Working Capital | 6.86 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
About Evoke Pharma Performance
By examining Evoke Pharma's fundamental ratios, stakeholders can obtain critical insights into Evoke Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evoke Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 524.00 | 619.04 | |
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.68) | (0.72) |
Things to note about Evoke Pharma performance evaluation
Checking the ongoing alerts about Evoke Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evoke Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evoke Pharma is way too risky over 90 days horizon | |
| Evoke Pharma appears to be risky and price may revert if volatility continues | |
| Evoke Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10.25 M. Net Loss for the year was (5.35 M) with profit before overhead, payroll, taxes, and interest of 13.99 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02. | |
| Evoke Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Evoke Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evoke Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Evoke Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evoke Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evoke Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evoke Pharma's stock. These opinions can provide insight into Evoke Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.38) | Revenue Per Share | Quarterly Revenue Growth 0.614 | Return On Assets | Return On Equity |
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.